Orient Electric Q1 Results: Revenue up 1.9% YoY to Rs 769 crore, net profit jumps 21%
Net profit for the period rose to Rs 17.52 crore, a 21% increase from Rs 14.34 crore in Q1 FY25. The improvement in bottom line comes on the back of better cost control and improved margins.
EBITDA for the quarter stood at Rs 46 crore compared to Rs 40 crore in the previous year, reflecting a growth of 15%. EBITDA margin expanded to 6% from 5.31% YoY.
Total expenses increased slightly to Rs 747.90 crore from Rs 738.07 crore YoY. Profit before tax came in at Rs 23.66 crore versus Rs 19.26 crore a year earlier.
The company continues to focus on operational efficiency and product innovation to sustain its margin growth in the coming quarters.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
SPCE Stock Price Prediction: Where Virgin Atlantic Could Be by 2025, 2026, and 2030
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Analysts are saying that Virgin Atlantic (SPCE) could hit $36 by the year 2030. Bullish on SPCE? You can invest in Virgin Atlantic on SoFi with no commissions. If it's your first time signing up for SoFi,. Plus, get a 1% bonus if you transfer your investments and keep them there until December 31, 2025. Virgin Galactic Holdings Inc), the space tourism company founded by British billionaire Richard Branson, has had a turbulent year due to sharp price declines and analyst apathy. As of July 21, 2025, the stock has plummeted over 38% year-over-year, starkly contrasting the S&P 500's nearly 4.9% increase during the same period. Analyst sentiment toward Virgin Galactic remains mixed. Only one analyst has issued a Buy recommendation, while the majority have rated the stock as a Hold or Sell. However, institutional ownership of the company exceeds 27%, indicating at least a moderate level of institutional confidence. Despite the stock's recent struggles, consensus price targets remain relatively high compared to the company's current market price, suggesting that analysts believe the company has potential for future growth. Don't Miss: Be part of the breakthrough that could replace plastic as we know it — invest in Timeplast before the July 31st deadline and help revolutionize a $1.3T industry. Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." Here's how you can earn passive income with just $100 today. It's worth noting that Virgin Galactic has been a popular target for short sellers and meme stock enthusiasts and was one of the stocks that saw a short squeeze unfold during the saga of GameStop Corp.. This increased interest has likely contributed to the stock's volatility and price decline and it remains to be seen how these factors will influence shares in the future. Virgin Galactic Stock Price Prediction for 2025 A good place to start for Virgin Galactic stock predictions is the current market price of $4.31. The stock has had a rough ride for most of 2024 and seems to continue in 2025. Technical analysis indicates the maximum price in 2025 is expected to be $4.05. This represents a negative change of around 6%. The minimum is projected to be around $3.80, leading to an average stock price of $3.90. Overall, SPCE's stock price is expected to decrease gradually throughout the rest of 2025. Anticipation of the company's spaceflights is growing and the company's first commercial launch is expected to generate significant media attention and investor interest. Also of note is the current level of short interest: over 25% of the float is currently sold short, which is a level worth keeping an eye on for future short squeezes. Virgin Galactic Stock Price Prediction for 2026 The year 2026 is shaping up to be a big one for Virgin Galactic stock. Investor confidence could also reach the stratosphere if the company can begin consistently scheduling commercial spaceflights. The company has seen revenue increases since 2024, but costs have also gone up and the firm reported a loss of $23 million in the most recent quarter in 2024. Despite the expanding losses, analysts are mixed on the stock. Citizen space travel likely appeals to only the wealthiest clients initially and the company will need to battle for market share with private competitors like SpaceX and Blue Origin. Price targets range from a minimum of $3.68 to a maximum of $3.81, representing a decrease of 11.71% from the current levels. Virgin Galactic Stock Price Prediction for 2030 With analyst price targets looking more like dart throws than precise projections, calculating where the Virgin Galactic stock price will be in 2030 depends on their ability to get citizens home from space safely and efficiently. If commercial space travel becomes a lucrative stock sector, there's no reason Goldman Sachs's sky-high price target of $36 couldn't be a reality by 2030. But remember, no company has ever attempted what Virgin Galactic is trying to accomplish. Even if it continues progressing toward the stars, volatility and uncertainty could keep SPCE stock grounded for long periods. Use caution and be sure to update your thesis if the company's fortunes change. Is Virgin Galactic Stock Right For You? When considering an investment in Virgin Galactic stock, you'll need to consider several key factors. The stock's sharp 37% decline in year-over-year share price is evidence of the company's current challenges. Analyst sentiment remains mixed – 1 out of 12 analysts rate the stock as a Buy and price targets are scattered across the landscape. Additionally, the stock has a large amount of short interest, adding a potential element of short squeeze volatility given its popularity within the meme stock community. Speculative short interest in volatile stocks like SPCE can cause unpredictable price swings. However, despite these concerns, the consensus price target on SPCE shares still suggests a double-digit upside, offering hope for long-term investors who believe in Virgin Galactic's future trajectory. Methodology for Stock Price Prediction Predicting the stock price of an aerospace tourism company with goals as lofty as Virgin Galactic's is a complex task that requires careful consideration of various factors. Given its industry and potential regulatory hurdles, analyzing the company's financial and technical data requires more than typical tech stock analysis. Flying people into space on a commercial aircraft is unprecedented and determining the profitability of such an endeavor is full of uncertainties. When forecasting Virgin Galactic's future stock price, we primarily relied on the following three concepts: Technical analysis: Technical indicators can often predict short-term price movements. Analyzing patterns, volume changes and indicators like support and resistance can help identify potential trading opportunities. While technical analysis can be valuable for short-term predictions, fundamental factors should also be considered if you invest with a long-term outlook. Fundamental analysis: Understanding Virgin Galactic's financial health is crucial for long-term investment decisions. Factors such as revenue growth, profitability, debt levels and investor sentiment provide insights into the company's prospects. For example, if Virgin Galactic announces an increase in ticket sales and reports a few successful spaceflight launches, the stock price could see a positive impact. Analyst projections and price targets: Relying on analyst ratings and price targets can be helpful, as they provide expert opinions and consensus on the company's future. While individual analysts may have varying perspectives, their collective analysis can offer valuable information about expected price movements and long-term stability. By combining these approaches, investors can make more informed decisions about Virgin Galactic's stock and assess its potential for long-term growth. No type of stock analysis will produce winners with 100% certainty, so combining multiple approaches is the best way to improve accuracy when learning how to buy stocks. See Next: $100k+ in investable assets? Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes – no cost, no obligation. Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." Here's how you can earn passive income with just $10, starting today. This article SPCE Stock Price Prediction: Where Virgin Atlantic Could Be by 2025, 2026, and 2030 originally appeared on
Yahoo
2 hours ago
- Yahoo
1 Super Artificial Intelligence (AI) Stock Billionaire Bill Gates Has 25% of His Foundation's Portfolio Invested In
Key Points The Gates Foundation holds a substantial number of Microsoft shares. Microsoft has become a top player in offering artificial intelligence models. However, the stock is starting to appear somewhat pricey compared to its peers. 10 stocks we like better than Microsoft › Bill Gates is a well-known entrepreneur, having co-founded Microsoft (NASDAQ: MSFT) in the mid-1970s. This made him a fortune, and he constantly ranks among the richest people in the world. He established the Gates Foundation Trust, one of the world's most well-funded foundations. By examining its holdings, investors can gain insight into what one of the world's brightest minds considers top stock picks, and they've identified an AI stock that has been a stellar performer in recent years. In fact, the stock has more than doubled since the start of 2023 alone. What is this stock? It's none other than Microsoft. Microsoft is the foundation's top holding This really shouldn't come as a surprise to anyone. Bill Gates runs the fund, so he will fill it with a company that he thinks will succeed. Most of this stock was donated from Gates' wealth; however, if the foundation didn't think Microsoft was set to succeed, they would have sold it a long time ago and moved on to something else. About 25% of the foundation's worth is tied up in Microsoft stock, valued at around $10.7 billion. That's a concentrated bet for a charitable foundation, but it has worked out well with Microsoft's recent success. Microsoft has emerged as a top AI pick due to its role as a facilitator in the space. It isn't developing its own generative AI model; instead, it's offering many of the leading ones on its cloud computing platform, Azure. Developers can choose from OpenAI's ChatGPT, a leading option, Meta Platforms' Llama, DeepSeek's R1 (a more affordable alternative from China), or xAI's Grok, a company founded by Elon Musk. By offering a wide range of generative AI models, Microsoft isn't locking its clients into a single provider. This has made Azure a top choice for building AI models on, which is why it has outgrown its peers in recent quarters. We'll get an update on how the other cloud computing providers -- namely Alphabet's Google Cloud and Amazon's Amazon Web Services (AWS) -- in the next few weeks, but I'd be shocked if Azure isn't growing quicker than they are. Azure has become a top platform for building AI applications, but has it done enough to make Microsoft a top buy now? Microsoft's stock is starting to look a bit pricey for its growth If Microsoft derived all of its revenue from Azure, I'd be a buyer at nearly any price. However, Microsoft has other product lines that aren't growing as quickly, which slows the company's overall growth pace. In its latest period -- the third quarter of fiscal 2025 -- overall revenue rose to $70.1 billion at a 13% pace. While Microsoft doesn't break out the revenue generated by Azure, we know from prior information that it accounts for over half of the Intelligent Cloud division, which brought in $26.8 billion during Q3 (ending March 31). They do provide Azure's growth rate, which was Microsoft's top-performing division in Q3, rising 33% year over year. Microsoft's diluted earnings per share also rose an impressive 18%, but is that fast enough to justify its valuation? Microsoft trades at nearly 40 times trailing earnings, which is a very expensive price tag and exceeds its recent highs reached during the AI arms race period. Wall Street analysts project $15.14 in earnings per share for fiscal 2026 (ending June 30, 2026), which indicates the stock trades at 33.7 times forward earnings. That's still a high valuation, and investors need to start being a bit cautious when stocks reach that level, especially when they're growing at Microsoft's pace. Yes, Microsoft is growing faster than the market, but it's not growing as fast as some of its peers. Take Meta Platforms, for example. It trades at 28 times trailing earnings and grew revenue at a 16% pace during its last quarter with 36% earnings-per-share growth. That's a cheaper stock growing faster, which should cause Microsoft investors to question whether it's the best big tech stock to be in right now. Numerous other big tech stocks have better growth numbers and cheaper valuations than Microsoft. Although it's a dominant company, it's starting to look a bit expensive compared to its peers. Should you buy stock in Microsoft right now? Before you buy stock in Microsoft, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Microsoft wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Keithen Drury has positions in Alphabet, Amazon, and Meta Platforms. The Motley Fool has positions in and recommends Alphabet, Amazon, Meta Platforms, and Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. 1 Super Artificial Intelligence (AI) Stock Billionaire Bill Gates Has 25% of His Foundation's Portfolio Invested In was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
2 Healthcare Stocks That Are Losing to the S&P 500 This Year
Key Points Novo Nordisk and Regeneron have encountered challenges recently. Both companies are significantly trailing the market this year. These healthcare leaders still could perform well in the long run. 10 stocks we like better than Novo Nordisk › Even with all the volatility and the flirting with bear-market territory, the S&P 500 index is well in the green this year, up about 8% since early January. Some stocks haven't been so lucky, though. Novo Nordisk (NYSE: NVO) and Regeneron Pharmaceuticals (NASDAQ: REGN), two leading drugmakers, have underperformed for most of the year, significantly lagging the broader market. These healthcare giants are facing some headwinds, but does that mean investors should steer clear of them? Let's find out. 1. Novo Nordisk Novo Nordisk has been facing several challenges that predate this year. It encountered a clinical setback for what Wall Street thought was a promising weight management candidate. Furthermore, the company's financial results, although strong when compared to its similarly sized peers, were not seen as sufficient because it's held to a higher standard. These challenges have led to a terrible performance this year. Novo Nordisk's shares are down by 18% year to date, significantly lagging the S&P 500. However, the stock might be a steal right now. The company has made several moves that should allow it to recover. Novo Nordisk's pipeline, especially in diabetes and weight management, remains one of the strongest in the industry. It recently initiated a phase 3 study for amycretin -- its next-generation GLP-1 medicine -- in both subcutaneous and oral formulations. It requested regulatory approval in the U.S. for an oral version of semaglutide, its well-known medicine marketed as Wegovy for weight loss and as Ozempic for diabetes management. Novo Nordisk has also penned several licensing deals that have expanded its pipeline in weight management. The company should launch at least one new medicine in its core therapeutic area within the next few years. Financial results should remain strong as Ozempic and Wegovy continue driving solid revenue growth. Considering the stock's sell-off over the past years, shares now look more than reasonably valued relative to Novo Nordisk's growth potential. Their forward price-to-earnings ratio of 16.9 is in line with the healthcare industry's average of 16.5 as of this writing. However, Novo Nordisk typically grows its revenue and earnings faster than its peers. That makes its stock attractive at current levels, based on its growth potential. 2. Regeneron Pharmaceuticals Regeneron is facing biosimilar competition for Eylea, a medicine for wet age-related macular degeneration that was once one of its biggest growth drivers. Sales of the medicine have dropped, dragging total revenue down with them. That's the most important reason why Regeneron's shares are down by 19% since the year started. However, the stock is still attractive. The biotech might go through a period of its top line declining, but it can still recover. Here are three reasons why. First, the company's newer, higher-dose (HD) formulation of Eylea is taking market share away from its previous version. HD Eylea is performing well and will grow even faster once it earns some label expansions. Second, Regeneron has a deep pipeline that's expected to yield new brand approvals. Earlier this month, it earned the green light for Lynozyfic, a cancer medicine, in the U.S. One of its more promising candidates is a gene therapy for one type of genetic deafness, which is showing incredible potential in clinical trials. Regeneron should move beyond Eylea thanks to newer approvals. Third, the company's most important product, Dupixent, an eczema treatment, is performing exceptionally well. The medicine has earned important label expansions in recent years, including in treating chronic obstructive pulmonary disease (COPD) and a rare skin condition called bullous pemphigoid. Dupixent will maintain its upward growth trajectory for a while. Here's one more reason to invest in Regeneron: The company is committed to returning capital to shareholders. It recently initiated a dividend and has a robust share-buyback program in place. The stock might be moving in the wrong direction right now, but those willing to hold onto it for five years or more could see superior returns over the long run. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Are Losing to the S&P 500 This Year was originally published by The Motley Fool Connectez-vous pour accéder à votre portefeuille
